- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Implicity Appoints Jon Hunt, PhD, as Chief Commercial Officer
Hunt joins the company from HeartBeam.
Jon Hunt, PhD, is joining Implicity as chief commercial officer.
Previously, Hunt worked for HeartBeam, a cardiac technology company, as an executive vice president and chief business officer. He has worked in the cardiovascular device industry for nearly 40 years.
In a press release, CEO and co-founder of Implicity Arnaud Rosier, MD, PhD, said, “Having an executive of Jon's caliber and experience is key to achieving our goal of becoming the leader in remote cardiac monitoring in the U.S. market. Jon brings extensive experience in the CRM/EP market and a proven track record of scaling startup companies and building commercial teams. We look forward to his guidance and expertise as we continue to build on our successes and provide healthcare professionals nationwide with more effective solutions for managing heart disease.”.
Implicity is a digital medtech software company that produces a platform that collects and standardizes data from a variety of implantable cardiac devices from different companies.
Source
(Sept. 27, 2023); Implicity; Implicity Expands Senior Leadership Team with New US Chief Commercial Officer; https://www.prnewswire.com/news-releases/implicity-expands-senior-leadership-team-with-new-us-chief-commercial-officer-301939282.html
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
